Day One Biopharmaceuticals, Inc. (DAWN) Stock Analysis

Day One Biopharmaceuticals, Inc. (DAWN) Healthcare & Pipeline Overview

Day One Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing targeted therapies for genetically defined cancers. Its primary focus is on DAY101, an oral brain-penetrant kinase inhibitor in Phase II for pediatric relapsed/progressive low-grade glioma, addressing significant unmet medical needs in oncology.

What Is the Investment Thesis for DAWN?

Day One Biopharmaceuticals, Inc. presents a research profile centered on its clinical-stage pipeline targeting genetically defined cancers, addressing significant unmet medical needs. The primary value driver is DAY101, an oral brain-penetrant RAF kinase inhibitor currently in a Phase II trial for pediatric relapsed/progressive low-grade glioma. Positive clinical data from this trial, followed by successful regulatory submissions and potential market approval, represent key growth catalysts. The company's focus on a niche, high-need pediatric oncology indication could facilitate accelerated regulatory pathways. While current financials reflect a clinical-stage profile with a P/E of -504.10, a profit margin of -67.8%, and negative free cash flow of $-0.06B, indicating substantial R&D investment, the gross margin of 89.1% suggests strong profitability potential upon commercialization. Risks include the inherent uncertainties of clinical development, potential trial failures, and the need for significant capital to fund ongoing research and future commercialization efforts. The company's beta of -1.75 indicates a high degree of volatility, which is common for early-stage biotechnology firms.

Based on FMP financials and quantitative analysis

DAWN Key Highlights

Market capitalization of $2.22B reflects investor valuation of its clinical-stage pipeline and future potential.

• P/E ratio of -504.10 and a profit margin of -67.8% are typical for a clinical-stage biopharmaceutical company investing heavily in R&D.
• Gross margin of 89.1% indicates strong potential profitability if lead candidates achieve commercialization.
• Free Cash Flow (FCF) of $-0.06 billion underscores the significant capital requirements for ongoing drug development and clinical trials.
• Beta of -1.75 suggests high volatility, characteristic of early-stage biotechnology firms with binary clinical trial outcomes.

Who Are DAWN's Competitors?

DAWN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are DAWN's Key Strengths?

Lead candidate DAY101 addresses high unmet medical need in pediatric low-grade glioma.

• Focus on genetically defined cancers aligns with precision medicine trends.
• DAY101 is an oral, brain-penetrant inhibitor, a critical feature for CNS tumors.
• High gross margin potential (89.1%) upon commercialization.

What Are DAWN's Weaknesses?

Clinical-stage company with no commercialized products, leading to negative profitability and FCF.

• Significant reliance on the success of a limited number of pipeline candidates.
• High R&D expenses inherent in biopharmaceutical development.
• Negative P/E ratio of -504.10 reflects current lack of earnings.

What Could Drive DAWN Stock Higher?

DAWN catalyst: Public release of Phase II clinical trial data for DAY101 in pediatric relapsed/progressive low-grade glioma, expected to provide critical insights into its efficacy and safety profile.

• Potential initiation of Phase III clinical trials for DAY101, contingent on positive Phase II results and regulatory feedback, marking a significant step towards commercialization.
• Continued patient enrollment and progression of clinical trials for Pimasertib, which could provide additional pipeline validation and future growth opportunities.
• Strategic discussions and potential partnerships aimed at accelerating development or expanding the commercial reach of pipeline assets.

What Are the Key Risks for DAWN?

Negative return on equity (-23.4%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failure for DAY101 or Pimasertib, which would significantly impact the company's valuation and future prospects, given its clinical-stage nature.
• Regulatory delays or non-approval by health authorities such as the FDA or EMA, which could postpone or prevent market entry for its drug candidates.
• Significant cash burn and reliance on external financing to fund extensive research and development activities, evidenced by a negative free cash flow of $-0.06B.
• Intense competition from other biotechnology and pharmaceutical companies developing targeted therapies for oncology, potentially impacting market share and pricing power.
• High stock price volatility, indicated by a beta of -1.75, reflecting the inherent risks and speculative nature of investments in early-stage biopharmaceutical companies.

What Are the Growth Opportunities for DAWN?

• Successful Commercialization of DAY101 in Pediatric Low-Grade Glioma: The primary growth driver for Day One Biopharmaceuticals is the successful completion of the Phase II clinical trial for DAY101 in pediatric patients with relapsed/progressive low-grade glioma, followed by regulatory approval and commercial launch. This specific indication represents a significant unmet medical need, with limited effective treatment options for children facing this challenging brain tumor. The market for pediatric oncology drugs, while smaller than adult indications, often benefits from accelerated review pathways and orphan drug designations, potentially leading to faster market entry. The addressable market, though niche, commands premium pricing due to the severity of the condition and the lack of alternatives, offering substantial revenue potential for a first-in-class or best-in-class therapy.
• Expansion of DAY101 into Additional Indications: Beyond its current focus on pediatric low-grade glioma, DAY101, as a pan-RAF kinase inhibitor, holds potential for label expansion into other genetically defined cancers driven by RAF mutations. Many adult and pediatric solid tumors are characterized by dysregulated RAF signaling, suggesting a broader market opportunity for DAY101. Successful clinical development in new indications would significantly expand the drug's total addressable market and revenue streams. This strategy allows the company to leverage its existing research and development investment in DAY101 across multiple patient populations, diversifying its risk and enhancing its long-term growth prospects within the oncology therapeutic area.
• Advancement and Commercialization of Pimasertib: The development of Pimasertib, an oral small molecule inhibitor of MEK1/2, represents another significant growth opportunity. MEK inhibitors are a validated class of targeted therapies in oncology, and Pimasertib's progress through clinical trials could unlock new therapeutic avenues for Day One. If Pimasertib demonstrates favorable efficacy and safety profiles, it could address other genetically defined cancers where MEK pathway dysregulation is a driver, either as a monotherapy or in combination with other agents. Successful development and commercialization of Pimasertib would diversify Day One's product portfolio, reducing reliance on DAY101 and strengthening its position as a multi-product oncology biotechnology company.
• Strategic Pipeline Expansion through Discovery or In-licensing: Day One Biopharmaceuticals' long-term growth will also be driven by its ability to replenish and expand its pipeline of targeted oncology therapies. This could involve internal drug discovery efforts, leveraging its expertise in genetically defined cancers, or through strategic in-licensing or acquisition of promising early-stage assets. Expanding the pipeline with novel mechanisms of action or targeting different cancer types would ensure sustained growth beyond its current lead candidates. A robust and diversified pipeline is crucial for clinical-stage biopharmaceutical companies to mitigate the inherent risks of drug development and maintain a competitive edge in the rapidly evolving oncology market.
• Leveraging Expertise in Brain-Penetrant Therapies: Day One's focus on developing DAY101 as an oral brain-penetrant inhibitor highlights a core competency in addressing central nervous system (CNS) cancers. Many systemic therapies struggle to cross the blood-brain barrier, limiting their effectiveness against brain tumors. This specialized expertise could be leveraged to develop or acquire other brain-penetrant compounds for various CNS indications, both oncological and potentially neurological. The market for effective brain tumor therapies remains significantly underserved, and establishing a leadership position in this challenging area could provide a sustainable competitive advantage and open up substantial future growth avenues for the company.

What Are DAWN's Competitive Advantages?

• Specialized focus on genetically defined cancers, particularly in pediatric oncology, addressing niche markets.
• Development of brain-penetrant therapies like DAY101, overcoming a significant challenge in treating CNS tumors.
• Proprietary drug candidates (DAY101, Pimasertib) protected by intellectual property.
• Expertise in kinase inhibition and targeted therapy development within oncology.

What Does DAWN Do?

Day One Biopharmaceuticals, Inc., incorporated in 2018 and headquartered in South San Francisco, California, operates as a clinical-stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for patients afflicted with genetically defined cancers. The company's strategic focus is on addressing significant unmet medical needs within oncology, particularly in areas with limited treatment options where precision medicine can offer substantial advantages. Its lead product candidate, DAY101, represents a cornerstone of its pipeline and therapeutic strategy. DAY101 is an oral, brain-penetrant type II pan-rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. This candidate is currently undergoing a pivotal Phase II clinical trial, specifically targeting pediatric patients diagnosed with relapsed/progressive low-grade glioma, a challenging form of brain tumor with often devastating prognoses and limited effective treatment alternatives. The development of DAY101 underscores Day One's commitment to precision medicine, aiming to deliver therapies that specifically target the molecular drivers of cancer, thereby potentially improving efficacy and reducing off-target toxicities. Beyond DAY101, the company is also advancing Pimasertib, another promising compound in its development portfolio. Pimasertib is an oral small molecule inhibitor designed to target mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). This dual-target inhibition strategy aims to disrupt key signaling pathways critically involved in cancer cell proliferation, differentiation, and survival, offering another avenue for targeted therapeutic intervention. Day One Biopharmaceuticals positions itself within the highly specialized and innovative segment of the biotechnology industry, focusing on areas where genetic insights can lead to more effective and less toxic treatments. With a dedicated team of 181 employees, the company is committed to navigating the complex landscape of drug discovery, clinical development, and eventual commercialization to bring novel, life-changing treatments to patients globally.

What Products and Services Does DAWN Offer?

• Develops and commercializes targeted therapies for patients with genetically defined cancers.
• Focuses on precision medicine approaches to treat oncology indications with high unmet needs.
• Lead product candidate is DAY101, an oral brain-penetrant type II pan-RAF kinase inhibitor.
• DAY101 is currently in Phase II clinical trials for pediatric patients with relapsed/progressive low-grade glioma.
• Also developing Pimasertib, an oral small molecule inhibitor of MEK1/2.
• Conducts extensive clinical research and development to advance its pipeline.
• Aims to bring novel treatments to market for challenging cancer types.
• Headquartered in South San Francisco, California, with 181 employees.

How Does DAWN Make Money?

• Engages in research and development of novel drug candidates for oncology.
• Seeks to obtain regulatory approvals for its drug candidates through clinical trials.
• Plans to commercialize approved therapies, generating revenue from drug sales.
• Potentially enters into licensing agreements or partnerships for drug development and commercialization.

What Industry Does DAWN Operate In?

Day One Biopharmaceuticals operates within the highly specialized and innovation-driven biotechnology industry, specifically focusing on oncology. The broader healthcare sector is experiencing a significant shift towards precision medicine, where therapies are tailored to the genetic profiles of individual patients' cancers. This trend is driven by advancements in genomic sequencing and a deeper understanding of molecular disease pathways. Day One's strategy aligns directly with this trend, positioning it within the targeted therapy segment. The competitive landscape in oncology biotechnology is intense, characterized by numerous companies pursuing novel drug candidates. However, Day One differentiates itself through its focus on genetically defined cancers and its lead candidate, DAY101, targeting pediatric low-grade glioma, an area with substantial unmet medical need and fewer established therapeutic options. The company's approach to developing brain-penetrant inhibitors addresses a critical challenge in treating central nervous system tumors, where many conventional therapies struggle to cross the blood-brain barrier effectively.

Who Are DAWN's Key Customers?

• Pediatric patients with relapsed/progressive low-grade glioma (target for DAY101).
• Patients with other genetically defined cancers (potential future indications for DAY101 and Pimasertib).
• Oncologists and healthcare providers who prescribe targeted cancer therapies.
• Hospitals and cancer treatment centers utilizing specialized oncology drugs.

Wall Street analysts project Day One Biopharmaceuticals, Inc. revenue of about $240.4M for fiscal 2026, with EPS near $-0.78. The estimate reflects 6 contributing analysts.

Day One Biopharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 18.80 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Day One Biopharmaceuticals, Inc. stands at -23.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -21.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.02 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.8%, the inverse of the P/E and a quick read on earnings relative to price.

Day One Biopharmaceuticals, Inc. (DAWN) Valuation Context

Valued at $2.22B, DAWN is classified as a mid-cap stock.

Company Profile

Day One Biopharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Brisbane, US. The company is led by CEO Jeremy Bender. DAWN has traded publicly since 2021.

DAWN Financials

DAWN Latest News

Latest Day One Biopharmaceuticals, Inc. Analysis

DAWN Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources